Science to practice: can theranostic fullerenes be used to treat brain tumors?
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 21931135.
- Also identified by DOI 10.1148/radiol.11111636.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In an orthotopic brain tumor mouse model, it was shown that convection-enhanced intratumoral delivery of a theranostic metallofullerene (f-Gd₃N@C₈₀) labeled with lutetium 177 (¹⁷⁷Lu) and tetraazacyclododecane tetraacetic acid (DOTA) (¹⁷⁷Lu-DOTA-f-Gd₃N@C₈₀) increases median survival from 21 to 52 days, with a prolonged metallofullerene tumor retention that can be visualized with magnetic resonance (MR) imaging.
Medical subject headings
- Brain Neoplasms
- Glioblastoma
- Lutetium
- Radioisotopes